Print this page
Radiation
-
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease.
Protocol: 072207Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Colon -
Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers.
Protocol: 072401Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Other Digestive Organ -
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma.
Protocol: 072402Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Pancreas -
A Phase 1/Randomized Phase 2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma.
Protocol: 072403Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Pancreas -
A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer.
Protocol: 072407Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Anus -
A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula.
Protocol: 072501Principal Investigator:
- Brett Ecker
Applicable Disease Sites: Pancreas -
SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined with Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men with Newly Diagnosed Metastatic Prostate Cancer. (Multi-center)
Protocol: 081707Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Prostate -
Randomized Phase III Trial Incorporating Abiraterone Acetate With Prednisone and Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy.
Protocol: 082003Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*).
Protocol: 082101Applicable Disease Sites: Prostate
-
Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE).
Protocol: 082104Principal Investigator:
- Tina Mayer
Applicable Disease Sites: Prostate -
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation.
Protocol: 082201Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Prostate -
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.
Protocol: 082210Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition.
Protocol: 082304Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer.
Protocol: 082305Principal Investigator:
- Lara Hathout
Applicable Disease Sites: Kidney -
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-Based Chemotherapy.
Protocol: 082306Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate -
A Phase 3, Randomized, Open-Label Study of MK-5684 (004) Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA).
Protocol: 082307Principal Investigator:
- Biren Saraiya
Applicable Disease Sites: Prostate